STOCK TITAN

Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Artelo Biosciences, Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023.
Positive
  • None.
Negative
  • None.

SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it will be participating in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

Gregory Gorgas, CEO of Artelo Biosciences, is scheduled to present on September 13, 2023 at 2:00 PM Eastern Time. The presentation will be webcast live on the conference event platform, which can be accessed at https://journey.ct.events/view/a3fb36ce-8e0f-41c1-b530-feebded86361 and on the investor relations section of Artelo’s website at https://ir.artelobio.com/.

Management will be participating in one-on-one meetings with qualified members of the investor community throughout the conference in New York City. To request a meeting, please contact ARTL@crescendo-ir.com

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com


Artelo Biosciences, Inc.

NASDAQ:ARTL

ARTL Rankings

ARTL Latest News

ARTL Stock Data

4.26M
3.20M
0.83%
0.78%
0.45%
Tobacco Manufacturing
Manufacturing
Link
United States of America
SOLANA BEACH

About ARTL

artelo biosciences is a biopharmaceutical company dedicated to applying true biopharma discipline in leveraging past research and leading-edge, world-class science to accelerate the development and commercialization of a diverse portfolio of novel, endocannabinoid system modulating therapeutics. our programs have the potential to dramatically improve patient care in major markets. with our headquarters team in san diego, california, usa and our european office in dublin, ireland, artelo established a presence in key global biopharma innovation hubs with close access to world-class research expertise. artelo’s research and development leverages the skill, knowledge and experience of our collaboration partners in europe and north america.